{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:49:59Z","timestamp":1772120999049,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2014R1A2A2A09051812"],"award-info":[{"award-number":["NRF-2014R1A2A2A09051812"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ejphar.2015.03.010","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T07:11:48Z","timestamp":1427613108000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine A in a murine model of imiquimod-induced psoriasis"],"prefix":"10.1016","volume":"756","author":[{"given":"Chang-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.03.010_bib1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2014.1111","article-title":"Combined use of systemic agents for psoriasis: a systematic review","volume":"150","author":"Busard","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/exd.12448","article-title":"Skin-penetrating methotrexate alleviates imiquimod-induced psoriasiform dermatitis via decreasing IL-17-producing gamma delta T cells","volume":"23","author":"Byamba","year":"2014","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-008-9233-0","article-title":"Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial","volume":"29","author":"Caproni","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/dth.12139","article-title":"Complementary and alternative medicine use among patients with psoriasis","volume":"27","author":"Damevska","year":"2014","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejphar.2015.03.010_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ced.12062","article-title":"Systemic methotrexate therapy for psoriasis: past, present and future","volume":"38","author":"Dogra","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1189\/jlb.0212101","article-title":"Targeting the Th17 pathway in psoriasis","volume":"92","author":"Elloso","year":"2012","journal-title":"J, Leukoc. Biol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.12.9.1085","article-title":"Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis","volume":"12","author":"Fantuzzi","year":"2008","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.ejphar.2015.03.010_bib9","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/eji.201343801","article-title":"TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis","volume":"43","author":"Flutter","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2015.03.010_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","article-title":"Immunopathogenic mechanisms in psoriasis","volume":"135","author":"Gudjonsson","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1468-3083.2009.03358.x","article-title":"Topical corticosteroids in psoriasis: strategies for improving safety","volume":"24","author":"Horn","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2340\/00015555-0905","article-title":"Systemic combination treatment for psoriasis: a review","volume":"90","author":"Jensen","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-3083.2011.02526.x","article-title":"Glucosamine improved atopic dermatitis-like skin lesions in NC\/Nga mice by inhibition of Th2 cell development","volume":"73","author":"Kim","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-3083.2011.02659.x","article-title":"Therapeutic effects of combination using glucosamine plus tacrolimus (FK-506) on the development of atopic dermatitis-like skin lesions in NC\/Nga mice","volume":"75","author":"Kim","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.intimp.2013.01.005","article-title":"Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC\/Nga mice","volume":"15","author":"Kim","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib17","doi-asserted-by":"crossref","first-page":"e91146","DOI":"10.1371\/journal.pone.0091146","article-title":"Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2015.03.010_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1346-8138.12003","article-title":"Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: a pilot study","volume":"40","author":"Kwon","year":"2013","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2015.03.010_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/jid.2011.375","article-title":"Regulatory T cells: banned cells for decades","volume":"132","author":"Loser","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2015.03.010_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib24","first-page":"597","article-title":"IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation","volume":"118","author":"Ma","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2015.03.010_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.03.010_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2011.03990.x","article-title":"Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists","volume":"25","author":"Paul","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib28","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib29","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3892\/mmr.2014.2136","article-title":"Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17\/IL-23 axis","volume":"9","author":"Qin","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2015.03.010_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2230.2002.01148.x","article-title":"Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology","volume":"27","author":"Reynolds","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2012.11208.x","article-title":"Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data","volume":"167","author":"Rustin","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jdermsci.2013.03.006","article-title":"Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis","volume":"71","author":"Schaper","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.ejphar.2015.03.010_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib34","first-page":"319","article-title":"Psoriasis--pathophysiology, conventional, and alternative approaches to treatment","volume":"12","author":"Traub","year":"2007","journal-title":"Altern. Med. Rev."},{"key":"10.1016\/j.ejphar.2015.03.010_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1346-8138.12367","article-title":"Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod","volume":"41","author":"Ueyama","year":"2014","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/jid.2012.512","article-title":"IL-1R1 signaling facilitates Munro\u05f3s microabscess formation in psoriasiform imiquimod-induced skin inflammation","volume":"133","author":"Uribe-Herranz","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib38","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib39","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2015.03.010_bib40","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/ACI.0b013e3283574ccb","article-title":"Immunoregulation in cutaneous allergy: prevention and control","volume":"12","author":"Zielinski","year":"2012","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2015.03.010_bib41","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.4049\/jimmunol.175.11.7202","article-title":"Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response","volume":"175","author":"Zhang","year":"2005","journal-title":"J. Immunol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915001910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915001910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:21:03Z","timestamp":1757974863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915001910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":41,"alternative-id":["S0014299915001910"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.03.010","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine A in a murine model of imiquimod-induced psoriasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}